Clinical Trials Logo

Alzheimer's Disease clinical trials

View clinical trials related to Alzheimer's Disease.

Filter by:

NCT ID: NCT00164749 Completed - Alzheimer's Disease Clinical Trials

A Pilot Study of Curcumin and Ginkgo for Treating Alzheimer's Disease

Start date: October 2004
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to develop procedures for testing the effectiveness of curcumin on slowing Alzheimer's disease (AD) progression.

NCT ID: NCT00151502 Completed - Alzheimer's Disease Clinical Trials

To Evaluate the Safety and Effectiveness of Atorvastatin Plus a Cholinesterase Inhibitor in AD Patients.

Start date: November 2002
Phase: Phase 3
Study type: Interventional

The purpose of this study is to find out if atovastatin, when taken with a cholinesterase inhibitor, is effective for treating Alzheimer's disease.

NCT ID: NCT00151333 Completed - Alzheimer's Disease Clinical Trials

Study Evaluating SRA-333 in Mild to Moderate Alzheimer's Disease (AD)

Start date: February 2005
Phase: Phase 2
Study type: Interventional

To determine the safety and tolerability of multiple ascending fixed oral doses of SRA-333 in subjects with mild to moderate Alzheimer's disease.

NCT ID: NCT00142805 Completed - Alzheimer's Disease Clinical Trials

Tricaprilin in Mild to Moderate Alzheimer's Disease

Start date: November 4, 2004
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety, tolerability and effectiveness of tricaprilin administered once a day for ninety days in subjects with mild to moderate, probable Alzheimer's disease.

NCT ID: NCT00130429 Completed - Alzheimer's Disease Clinical Trials

Safety and Effect on Memory of PYM50028 in Mild Alzheimer's Disease

Start date: January 2004
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the effect of PYM50028 administered once daily for up to 12 weeks on the memory and other faculties of subjects with dementia due to Alzheimer's disease.

NCT ID: NCT00117403 Completed - Alzheimer's Disease Clinical Trials

Anti-Oxidant Treatment of Alzheimer's Disease

Start date: January 2006
Phase: Phase 1
Study type: Interventional

The purpose of this study is to examine the safety and effectiveness of two anti-oxidant treatment regimens in patients with mild to moderate Alzheimer's disease. The anti-oxidant treatments include vitamin E + C + alpha-lipoic acid, and Coenzyme Q (CoQ).

NCT ID: NCT00112073 Completed - Alzheimer's Disease Clinical Trials

AAB-001 in Patients With Mild to Moderate Alzheimer's Disease

Start date: April 2005
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the safety and tolerability of multiple doses of AAB-001 passive immunization in patients with mild to moderate Alzheimer's disease (AD).

NCT ID: NCT00106899 Completed - Alzheimer's Disease Clinical Trials

ADNI: Alzheimer's Disease Neuroimaging Initiative

Start date: July 2005
Phase: N/A
Study type: Observational

The purpose of this study is to examine how brain imaging technology can be used with other tests to measure the progression of mild cognitive impairment (MCI) and early Alzheimer's disease (AD). This information will aid future clinical trials by providing a standard assessment tool to measure the effects of treatments being studied.

NCT ID: NCT00105612 Completed - Aging Clinical Trials

Memory Aid for Informed Consent in Alzheimer's Research

Start date: September 2004
Phase: N/A
Study type: Interventional

The purpose of this trial is to test whether a memory and organizational aid in the form of a document that summarizes and simplifies a study's key points can improve the decision-making abilities and competency of mild to early moderate Alzheimer's disease (AD) patients.

NCT ID: NCT00104442 Completed - Alzheimer's Disease Clinical Trials

Study of the Effects of Current Drug Treatments on Levels of Certain Brain Chemicals in Alzheimer's Disease

Start date: October 2003
Phase: Phase 4
Study type: Interventional

Alzheimer's disease is a medical illness that damages the brain and causes problems with memory, mood and behavior. A substance called acetylcholine (ACh), which is naturally produced in the body, plays an important role in the normal functioning of the brain. In subjects with Alzheimer's disease, the level of ACh is greatly reduced. Currently, there are three commonly prescribed drugs used for treating the symptoms of Alzheimer's disease by helping to maintain the level of ACh in the brain. This study will evaluate how much each of these drugs changes the levels of certain brain chemicals that are known to, or may play an important role in, Alzheimer's disease and its symptoms.